Variables
|
PFS
|
OS
|
---|
Univariate analysis
|
Multivariate analysis
|
Univariate analysis
|
Multivariate analysis
|
---|
HR (95% CI) P
|
HR (95% CI) P
|
HR (95% CI) P
|
HR (95% CI) P
|
---|
Age (years)
|
<55
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
≥55
|
0.99 (0.67–1.44) 0.939
|
1.33 (0.80–2.20) 0.268
|
1.14 (0.67–1.92) 0.634
|
1.51 (0.75–3.04) 0.245
|
ASA
|
1–2
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
3–4
|
2.29 (1.37–3.84) 0.002
|
2.38 (1.26–4.51) 0.008
|
3.12 (1.64–5.90) < 0.001
|
3.24 (1.54–6.82) 0.009
|
Baseline CA-125 level (U/ml)
|
≤800
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
>800
|
1.04 (0.71–1.53) 0.826
|
1.14 (0.69–1.90) 0.605
|
0.79 (0.47–1.34) 0.382
|
0.93 (0.45–1.91) 0.838
|
FIGO stage
|
III
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
IV
|
0.91 (0.62–1.33) 0.629
|
0.74 (0.47–1.18) 0.210
|
0.75 (0.44–1.26) 0.277
|
0.62 (0.32–1.24) 0.177
|
Histology
|
Others
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
Mucinous
|
2.64 (1.54–4.50) < 0.001
|
2.31 (1.26–4.24) 0.007
|
4.69 (2.48–8.85) < 0.001
|
3.24 (1.54–6.82) 0.002
|
Clear cell
|
2.10 (1.30–3.42) 0.003
|
1.92 (1.12–3.29) 0.017
|
2.62 (1.37–4.99) 0.004
|
2.56 (1.21–5.30) 0.013
|
Residual disease
|
≤1 cm
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
>1 cm
|
2.86 (1.75–4.66) < 0.001
|
2.40 (1.43–4.04) 0.001
|
3.46 (1.89–6.33) < 0.001
|
2.43 (1.28–4.63) 0.007
|
Surgery extent
|
Standard
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
Radical
|
0.94 (0.64–1.39) 0.771
|
1.75 (1.02–2.99) 0.042
|
0.98 (0.57–1.67) 0.933
|
1.86 (0.97–3.56) 0.062
|
LND
|
No
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
Yes
|
0.67 (0.17–2.76) 0.004
|
0.33 (0.18–0.61) < 0.001
|
0.36 (0.09–1.49) 0.002
|
0.32 (0.16–0.62) 0.001
|
LN metastasis
|
No
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
1.00 (Reference)
|
Yes
|
1.03 (0.25–4.26) 0.074
|
2.89 (1.65–5.07) < 0.001
|
0.46 (0.11–1.97) 0.553
|
1.78 (0.74–4.32) 0.201
|
- PFS progression-free survival, OS overall survival, HR hazard ratio, CI confidence interval, ASA American Society of Anesthesiologists, CA-125 cancer antigen 125, FIGO Federation of Gynecology and Obstetrics, M/C Mucinous/Clear, LND lymph node dissection, LN lymph node